Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer: An active regimen for outpatient treatment Journal Article


Authors: Kris, M. G.; Gralla, R. J.; Kelsen, D. P.; Casper, E. S.; Burke, M. T.; Fiore, J. J.; Cibas, I. R.; Heelan, R. T.
Article Title: Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer: An active regimen for outpatient treatment
Abstract: Ninety patients with stage-3 non-small cell lung cancer were given vindesine (3 mg/sq m) plus mitomycin (10 mg/sq m). Data on response are available for 84 adequately treated individuals (93 per cent). For patients who had received no prior chemotherapy, the rate of major objective response was 36 percent (20/55). For previously treated patients the rate of major response was 17 percent (5/29). The drugs were routinely administered in the outpatient department without difficulty. Moderate or severe myelosuppression, neurotoxic, nephrotoxic, or pulmonary toxic effects, nausea, and vomiting occurred in less than 15 percent of all studied patients. Three-drug extravasation ulcerations occurred in 1,129 administrations of chemotherapy (0.3 percent). There were treatment-related deaths, one from sepsis and one from the combination of mitomycin-induced pulmonary and renal toxic effects. The combination of vindesine plus mitomycin is an active, well-tolerated outpatient regimen for patients with non-small cell lung cancer who have not previously received chemotherapy. Further trials are warranted to compare this regimen to other active combinations and to use it as a component of a program of treatment using alternating regimens of chemotherapy.
Keywords: major clinical study; cisplatin; fluorouracil; cancer combination chemotherapy; drug efficacy; methotrexate; neurotoxicity; lung toxicity; nephrotoxicity; gastrointestinal symptom; lung cancer; cyclophosphamide; vinblastine; gastrointestinal toxicity; kidney; sepsis; mitomycin c; vindesine; anthracycline derivative; drug therapy; mitomycin; adverse drug reaction; therapy; intravenous drug administration; nervous system; bone marrow depression; intoxication; digestive system; respiratory system; drug extravasation; human; priority journal; blood and hemopoietic system
Journal Title: Chest
Volume: 87
Issue: 3
ISSN: 0012-3692
Publisher: American College of Chest Physicians  
Date Published: 1985-03-01
Start Page: 368
End Page: 372
Language: English
DOI: 10.1378/chest.87.3.368
PROVIDER: scopus
PUBMED: 2982552
DOI/URL:
Notes: Article -- Export Date: 26 October 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David P Kelsen
    537 Kelsen
  2. Mark Kris
    869 Kris
  3. Robert T Heelan
    140 Heelan
  4. Ephraim S Casper
    108 Casper
  5. Richard J. Gralla
    69 Gralla